VLG vs. BXP, ANCR, DNL, EAH, STX, PXS, CHLL, CEL, MXC, and N4P
Should you be buying Venture Life Group stock or one of its competitors? The main competitors of Venture Life Group include Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Diurnal Group (DNL), ECO Animal Health Group (EAH), Shield Therapeutics (STX), Provexis (PXS), Chill Brands Group (CHLL), Celadon Pharmaceuticals (CEL), Argent BioPharma (MXC), and N4 Pharma (N4P). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Venture Life Group vs.
Beximco Pharmaceuticals (LON:BXP) and Venture Life Group (LON:VLG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.
Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.
In the previous week, Beximco Pharmaceuticals had 3 more articles in the media than Venture Life Group. MarketBeat recorded 3 mentions for Beximco Pharmaceuticals and 0 mentions for Venture Life Group. Beximco Pharmaceuticals' average media sentiment score of 0.02 beat Venture Life Group's score of 0.00 indicating that Beximco Pharmaceuticals is being referred to more favorably in the media.
1.7% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.5% of Venture Life Group shares are owned by institutional investors. 10.4% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Beximco Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Venture Life Group has a beta of 0.3, meaning that its share price is 70% less volatile than the S&P 500.
Venture Life Group received 48 more outperform votes than Beximco Pharmaceuticals when rated by MarketBeat users. Likewise, 72.90% of users gave Venture Life Group an outperform vote while only 64.67% of users gave Beximco Pharmaceuticals an outperform vote.
Beximco Pharmaceuticals has a net margin of 12.37% compared to Venture Life Group's net margin of 1.44%. Beximco Pharmaceuticals' return on equity of 10.99% beat Venture Life Group's return on equity.
Summary
Beximco Pharmaceuticals beats Venture Life Group on 9 of the 15 factors compared between the two stocks.
Get Venture Life Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Venture Life Group Competitors List
Related Companies and Tools
This page (LON:VLG) was last updated on 1/19/2025 by MarketBeat.com Staff
